Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 5/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640405 | 0.88 | MAPK1 (0.42) | MAPK1KMT2AESR2KDM4EMAPT | |
| SCHEMBL16640416 | 0.86 | MAPK1 (0.40) | MAPK1ESR2KDM4EMAPTTHRB | |
| SCHEMBL16640403 | 0.86 | MAPK1 (0.40) | MAPK1ESR2KDM4EMAPTTHRB | |
| SCHEMBL23982238 | 0.81 | STS (0.47) | MAPK1MEN1KMT2AMAPTUSP30 | |
| SCHEMBL30397321 | 0.81 | STS (0.47) | MAPK1MEN1KMT2AMAPTUSP30 | |
| SCHEMBL16640404 | 0.80 | MAPK1 (0.44) | MAPK1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL3318358 | 0.80 | MEN1 (0.49) | MAPK1MEN1KMT2ASTSPDE4B | |
| SCHEMBL940218 | 0.79 | MAPK1 (0.50) | MAPK1KDM4EUSP30GPR119 | |
| SCHEMBL19745334 | 0.79 | MAPK1 (0.50) | MAPK1KDM4EUSP30GPR119 | |
| SCHEMBL5651780 | 0.79 | MAPK1 (0.50) | MAPK1KDM4EUSP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057963-B1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9233953-B2 | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-9233953-B2 | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| WO-2015055698-A1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | SLC6A7, SLC7A11, SLC7A1 | MAPK1 2451/4885MEN1 1881/4885KMT2A 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.